Ipatasertib
- Generic Name
- Ipatasertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32ClN5O2
- CAS Number
- 1001264-89-6
- Unique Ingredient Identifier
- 524Y3IB4HQ
- Background
Ipatasertib has been used in trials studying the treatment of Cancer, Neoplasms, Solid Cancers, Breast Cancer, and Gastric Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 139
- Registration Number
- NCT03800836
- Locations
- 🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
🇦🇺St Vincents Hospital; Cardiopulmonary transplant Ambulatory Care Dept, Darlinghurst, New South Wales, Australia
🇦🇺Austin Hospital, Heidelberg, Victoria, Australia
A Trial of Ipatasertib in Combination With Atezolizumab
- Conditions
- Interventions
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 87
- Registration Number
- NCT03673787
- Locations
- 🇬🇧
Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, United Kingdom
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
- Conditions
- Interventions
- Drug: AlectinibDrug: VismodegibDrug: IpatasertibDrug: CarboplatinDrug: OlaparibDrug: ErlotinibDrug: CisplatinDrug: BevacizumabDrug: GemcitabineDrug: VemurafenibDrug: CobimetinibDrug: Trastuzumab Subcutaneous (SC)Drug: PertuzumabDrug: AtezolizumabDrug: PaclitaxelDrug: EntrectinibDrug: IvosidenibDrug: Pemigatinib
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 528
- Registration Number
- NCT03498521
- Locations
- 🇦🇺
Northern Cancer Institute, St Leonards, New South Wales, Australia
🇦🇺Blacktown Hospital, Blacktown, New South Wales, Australia
🇫🇮Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Conditions
- Interventions
- Drug: CapecitabineDrug: AtezolizumabDrug: Ribociclib (dose #1)Drug: Inavolisib (dose #2)Drug: AbemaciclibDrug: Trastuzumab DeruxtecanDrug: IpatasertibDrug: Sacituzumab GovitecanDrug: FulvestrantDrug: Ribociclib (dose #2)Drug: Inavolisib (dose #1)Drug: SGN-LIV1ADrug: Chemotherapy (Gemcitabine + Carboplatin or Eribulin)Drug: TocilizumabDrug: BevacizumabDrug: LetrozoleDrug: Nab-PaclitaxelDrug: InavolisibDrug: Selicrelumab
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 580
- Registration Number
- NCT03424005
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California San Diego Medical Center; Moores Cancer Center, La Jolla, California, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
Pre-operative Immunotherapy Combination Strategies in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 71
- Registration Number
- NCT03395899
- Locations
- 🇬🇧
Barts Health NHS Trust, London, United Kingdom
Prostate Cancer Biomarker Enrichment and Treatment Selection
- Conditions
- Interventions
- First Posted Date
- 2017-12-28
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 200
- Registration Number
- NCT03385655
- Locations
- 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT03341884
- Locations
- 🇺🇸
American Research Corporation Inc., San Antonio, Texas, United States
🇺🇸Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
🇺🇸New Orleans Center for Clinical Research, Knoxville, Tennessee, United States
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
- Conditions
- Interventions
- Drug: AtezolizumabDrug: DocetaxelDrug: RO6958688Drug: CPI-444Drug: LinagliptinDrug: Sacituzumab GovitecanDrug: BevacizumabDrug: CamonsertibDrug: CobimetinibDrug: IpatasertibDrug: PemetrexedDrug: EvolocumabDrug: TiragolumabOther: RadiationDrug: TocilizumabDrug: CarboplatinDrug: GemcitabineDrug: XL092
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 675
- Registration Number
- NCT03337698
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei City, Taiwan
🇪🇸Hospital Clinico Universitario de Valencia, Valencia, Spain
🇨🇳National Cheng Kung University Hospital; Gasterointestinal, Tainan City, Taiwan
A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 579
- Registration Number
- NCT03337724
- Locations
- 🇩🇪
Oncologianova GmbH - Gesellschaft für Innovationen in der Onkologie, Recklinghausen, Germany
🇺🇸Kaiser Permanente - Roseville, Roseville, California, United States
🇺🇸Kaiser Permanente - South San Francisco, South San Francisco, California, United States
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 138
- Registration Number
- NCT03280563
- Locations
- 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Univ of Pittsburgh Sch of Med; Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.